ATG38 Antibody

What is ATG38 and why is it important in autophagy research?

ATG38 is a fifth subunit of the autophagic Vps34/PIK3C3 complex that plays a crucial role in autophagy regulation. It functions primarily as part of the phosphatidylinositol 3-kinase (PtdIns3K) complex I, which is essential for initiating autophagosome formation. ATG38 bridges the coiled-coil I regions of Atg14 and Vps30 in the base of complex I, helping to stabilize the complex structure and promote its activity in autophagy induction . Understanding ATG38 is important because it represents a key regulatory point in the autophagy pathway, and disruptions in its function can impair autophagic flux, with implications for various diseases where autophagy dysfunction plays a role.

What are the key structural domains of ATG38 that antibodies can target?

ATG38 has two major domains that can be targeted by antibodies: an N-terminal MIT (microtubule-interacting and targeting) domain and a C-terminal homodimerization domain. The MIT domain is critical for binding to complex I and functional during starvation conditions . The C-terminal region forms a unique mushroom-like asymmetric homodimer with a 4-helix cap and a parallel coiled-coil stalk, as revealed by crystallography at 2.2 Å resolution . In fission yeast, ATG38 also contains a highly conserved AIM (Atg8-interacting motif) between residues 173 and 185, which mediates interaction with Atg8 . Antibodies targeting these specific domains can be valuable tools for investigating domain-specific functions.

How conserved is ATG38 across species, and how does this affect antibody selection?

ATG38 shows varying degrees of conservation across species. While the human ortholog NRBF2 shares similar domain organization with yeast Atg38 (both having N-terminal MIT domains and C-terminal homodimerization regions), they interact differently with their respective complexes . In fission yeast species, the most conserved region is not the MIT domain but rather a 13-amino-acid linear motif (the AIM) between residues 173-185 . This variability means researchers must carefully select antibodies appropriate for their target species. Cross-reactivity between species should not be assumed, and validation is necessary when applying antibodies across evolutionary boundaries.

What are the recommended methods for validating ATG38 antibody specificity?

To validate ATG38 antibody specificity, multiple complementary approaches should be employed:

• Western blotting with proper controls: Compare protein lysates from wild-type cells versus ATG38 knockout/knockdown cells to confirm specificity.

• Immunoprecipitation followed by mass spectrometry: Verify that immunoprecipitated proteins include ATG38 and known interaction partners (Vps30/Beclin1, Atg14, Vps15, Vps34).

• Recombinant protein analysis: Express tagged versions of ATG38 (full-length and domain-specific constructs) and test antibody recognition.

• Immunofluorescence comparison: Compare antibody staining patterns between wild-type and ATG38-deficient cells, looking for characteristic punctate structures that represent phagophore assembly sites (PAS) .

• Competition assays: Pre-incubation of antibodies with purified ATG38 protein should abolish specific signals.

For each validation method, it's critical to include appropriate positive and negative controls to ensure reliable interpretation of results.

How can researchers effectively use ATG38 antibodies to study autophagy regulation?

Researchers can effectively use ATG38 antibodies to study autophagy regulation through several approaches:

• Monitoring ATG38 localization changes: During autophagy induction, ATG38 relocates to the phagophore assembly site (PAS). Antibodies can be used in immunofluorescence microscopy to track this translocation and colocalization with other autophagy proteins .

• Analyzing complex formation: Immunoprecipitation with ATG38 antibodies can pull down the entire PtdIns3K complex I, allowing assessment of complex integrity under different conditions or following genetic manipulations.

• Studying post-translational modifications: Phosphorylation or other modifications of ATG38 might regulate its function. Antibodies recognizing total ATG38 can be used alongside modification-specific antibodies to assess regulatory mechanisms.

• Quantifying autophagy flux: Changes in ATG38 levels or localization can be correlated with autophagy markers like LC3/Atg8 processing to evaluate the relationship between ATG38 function and autophagic activity .

• Structure-function studies: Domain-specific antibodies can block particular interactions (e.g., with Atg14 or Atg8) to dissect the functional importance of different ATG38 domains.

What controls should be included when using ATG38 antibodies in immunoprecipitation experiments?

When performing immunoprecipitation (IP) experiments with ATG38 antibodies, several controls are essential:

• Input control: Include an aliquot of the starting material to confirm the presence of target proteins before IP.

• Isotype control: Use an irrelevant antibody of the same isotype to identify non-specific binding.

• Genetic controls: When possible, include samples from ATG38 knockout/knockdown cells to verify the specificity of pulled-down bands.

• Blocking peptide control: Pre-incubate the antibody with excess ATG38 peptide (used for immunization) to block specific binding sites.

• Complex component controls: Since ATG38 is part of a complex, verify co-immunoprecipitation of known partners like Vps34, Vps15, Vps30/Beclin1, and Atg14 .

• Condition-specific controls: Include both basal and autophagy-induced conditions (e.g., starvation, rapamycin treatment) to demonstrate condition-dependent interactions.

• Crosslinking controls: If using crosslinking methods to stabilize protein interactions, include non-crosslinked samples to distinguish direct from indirect interactions.

How can researchers utilize ATG38 antibodies to investigate the dynamics of PtdIns3K complex assembly?

Researchers can employ multiple sophisticated techniques with ATG38 antibodies to investigate PtdIns3K complex assembly dynamics:

• Sequential immunoprecipitation: Use ATG38 antibodies in tandem with antibodies against other complex components to determine subcomplexes and assembly intermediates.

• Proximity ligation assays (PLA): Combine ATG38 antibodies with antibodies against other complex members to visualize and quantify direct protein interactions in situ with nanometer resolution.

• Fluorescence recovery after photobleaching (FRAP): Use fluorescently-tagged ATG38 antibody fragments to monitor the dynamic exchange of ATG38 with the complex in living cells.

• Size-exclusion chromatography combined with antibody detection: Fractionate cell lysates and use ATG38 antibodies to identify different assembly states of the complex.

• Hydrogen-deuterium exchange mass spectrometry (HDX-MS): Use ATG38 antibodies to purify complexes for HDX-MS analysis, which can reveal conformational changes upon complex assembly, as demonstrated in previous studies that mapped interactions between the MIT domain of Atg38 and the coiled-coil regions of Atg14 and Vps30 .

• Single-molecule pull-down assays: Immobilize ATG38 antibodies to capture individual complexes for analysis of stoichiometry and assembly states.

What strategies can be used to study the interaction between ATG38 and Atg8 using specific antibodies?

To study the ATG38-Atg8 interaction using antibodies, researchers can implement these advanced strategies:

• Co-immunoprecipitation with domain-specific antibodies: Use antibodies targeting the AIM region (residues 173-185) versus other domains to determine which antibodies might block or preserve the ATG38-Atg8 interaction .

• Competitive binding assays: Develop assays where labeled Atg8 competes with ATG38 antibodies for binding to ATG38, particularly those antibodies that recognize the AIM region.

• FRET-based interaction assays: Combine fluorescently-labeled ATG38 antibody fragments with labeled Atg8 to detect interactions through fluorescence resonance energy transfer.

• Site-directed antibody targeting: Generate antibodies specifically recognizing the AIM (Atg8-interacting motif) in its free versus Atg8-bound states to probe the conformation changes during interaction .

• In situ proximity ligation: Use antibodies against ATG38 and Atg8 in proximity ligation assays to visualize their interactions at the phagophore assembly site.

• Mutation-specific antibodies: Develop antibodies that selectively recognize wild-type AIM versus mutated versions (e.g., F178A,V181A) to distinguish functional from non-functional ATG38 .

• ChIP-like crosslinking approaches: Adapt chromatin immunoprecipitation methods to study protein-protein interactions by crosslinking ATG38-Atg8 complexes and using antibodies to pull down the complexes.

How can researchers use ATG38 antibodies to study differences between yeast Atg38 and human NRBF2 functions?

Researchers can leverage ATG38 antibodies to investigate functional differences between yeast Atg38 and human NRBF2 through:

• Comparative immunoprecipitation: Use species-specific antibodies to pull down respective complexes and compare their composition and stoichiometry between species.

• Heterologous expression systems: Express yeast Atg38 in human cells (or NRBF2 in yeast) and use species-specific antibodies to assess functional complementation and complex integration.

• Domain-swapping experiments: Create chimeric proteins with domains from both Atg38 and NRBF2, then use domain-specific antibodies to track their localization and function.

• Structural epitope mapping: Use a panel of antibodies against different regions to identify structural differences between Atg38 and NRBF2, complementing existing structural data that shows Atg38 forms homodimers that engage a single complex I, while NRBF2 might function differently despite also forming homodimers .

• Cross-species antibody reactivity analysis: Determine which epitopes are conserved by testing cross-reactivity of antibodies, providing insight into evolutionary conservation of functional domains.

• Differential inhibition assays: Determine if antibodies against specific domains differentially affect Atg38 versus NRBF2 function in their respective species.

What are common pitfalls when using ATG38 antibodies, and how can researchers avoid them?

Common pitfalls when using ATG38 antibodies include:

• Cross-reactivity with related proteins: ATG38/NRBF2 belongs to a family of proteins with MIT domains. Validate antibody specificity against related proteins, especially in immunofluorescence applications.

• Low signal in basal conditions: ATG38 expression may be low under non-autophagy conditions. Consider enrichment methods (immunoprecipitation, subcellular fractionation) before detection.

• Epitope masking in complexes: The antibody epitope may be obscured when ATG38 is incorporated into the PtdIns3K complex. Try multiple antibodies targeting different regions or mild denaturation methods.

• Post-translational modifications affecting antibody recognition: Phosphorylation or other modifications might alter epitope accessibility. Compare results under different cellular conditions.

• Fixation artifacts in immunofluorescence: Different fixation methods can affect ATG38 localization detection. Compare paraformaldehyde, methanol, and other fixatives to determine optimal conditions.

• Homodimerization complicating quantification: Since ATG38 forms homodimers , quantitative analysis may not have linear relationship with protein levels. Use purified recombinant protein standards for calibration.

• Species-specific differences: Be aware that antibodies raised against yeast Atg38 may not recognize human NRBF2 and vice versa, despite their orthologous relationship .

What is the optimal protocol for immunofluorescence detection of ATG38 at the phagophore assembly site?

Optimal immunofluorescence protocol for detecting ATG38 at the phagophore assembly site:

• Cell preparation:

  • Induce autophagy through starvation (e.g., EBSS medium for mammalian cells, nitrogen starvation for yeast)

  • For better visualization, consider using Atg1/ULK1 knockout cells which accumulate early autophagy structures

• Fixation optimization:

  • Try both 4% paraformaldehyde (10 minutes, room temperature) and 100% ice-cold methanol (5 minutes, -20°C)

  • Paraformaldehyde better preserves GFP fluorescence if using tagged proteins

  • Methanol often provides better accessibility to membranous structures

• Permeabilization:

  • For paraformaldehyde-fixed cells: 0.1-0.3% Triton X-100 (10 minutes)

  • Include a brief digestion with 25 μg/ml digitonin for improved access to membrane-associated proteins

• Blocking:

  • 5% BSA with 0.1% saponin in PBS (1 hour, room temperature)

  • Include 5-10% normal serum from the species of secondary antibody origin

• Primary antibody incubation:

  • Dilute ATG38 antibody 1:100-1:500 in blocking buffer

  • Co-stain with established PAS markers (Atg8/LC3, Atg14)

  • Incubate overnight at 4°C in a humid chamber

• Visualization enhancement:

  • Consider tyramide signal amplification for low-abundance targets

  • Use high-sensitivity confocal or super-resolution microscopy (STED, STORM)

  • Counterstain with DAPI and include a marker for cell boundaries

• Controls:

  • Include ATG38-deficient cells as negative controls

  • Compare patterns in basal versus induced autophagy conditions

  • Use cells expressing fluorescently-tagged ATG38 as positive controls

How can researchers optimize western blot protocols for detecting low-abundance ATG38?

To optimize western blot detection of low-abundance ATG38:

• Sample preparation enhancements:

  • Enrich ATG38 through immunoprecipitation or subcellular fractionation

  • Use protease inhibitor cocktails with additional inhibitors specific for autophagy-related proteases

  • Consider crosslinking before lysis to preserve protein complexes

• Lysis optimization:

  • Try different lysis buffers (RIPA, NP-40, digitonin-based) to determine optimal extraction

  • Include phosphatase inhibitors to preserve post-translational modifications

  • Sonicate samples briefly to improve extraction of membrane-associated proteins

• Protein loading and separation:

  • Increase protein loading (50-100 μg per lane)

  • Use gradient gels (4-15% or 4-20%) for better resolution

  • Extend running time at lower voltage for improved separation

• Transfer modifications:

  • Optimize transfer conditions based on protein size (ATG38 ~26 kDa, homodimer ~52 kDa)

  • Use PVDF membranes with 0.2 μm pore size for smaller proteins

  • Consider semi-dry transfer systems with methanol-free buffers

• Signal enhancement strategies:

  • Use high-sensitivity ECL substrates or fluorescent secondary antibodies

  • Try biotin-streptavidin amplification systems

  • Consider overnight primary antibody incubation at 4°C with gentle agitation

• Blocking optimization:

  • Test different blocking agents (milk vs. BSA vs. commercial blockers)

  • Add 0.05% SDS to antibody dilution buffer to reduce background

  • Validate blocking efficiency with parallel negative controls

• Documentation:

  • Use long exposure times and high-sensitivity cameras

  • Consider digital stacking of multiple exposures

  • Use internal loading controls from the same blot (avoid stripping when possible)

How should researchers interpret changes in ATG38 localization versus expression levels during autophagy?

Interpreting ATG38 localization versus expression changes requires careful analysis:

• Differentiating mechanisms:

  • Localization changes primarily reflect regulatory targeting of existing protein

  • Expression level changes indicate transcriptional/translational regulation or protein stability changes

  • Both parameters should be measured independently and correlated with autophagy markers

• Localization analysis considerations:

  • Quantify the percentage of ATG38 in punctate structures (PAS) versus diffuse cytoplasmic distribution

  • Measure colocalization coefficients with known markers (Atg8/LC3, Atg14)

  • Track temporal dynamics during autophagy induction and resolution

  • In fission yeast, ATG38 recruitment to the PAS depends on its interaction with Atg8 via the AIM motif

• Expression level interpretation:

  • Normalize to multiple housekeeping proteins

  • Compare total protein levels (whole cell lysates) with the amount in specific fractions

  • Consider post-translational modifications affecting antibody recognition

  • Determine half-life through cycloheximide chase experiments

• Integrated analysis approach:

  • Correlate ATG38 changes with functional readouts of autophagy (Atg8/LC3 processing, cargo degradation)

  • Compare wild-type patterns with cells expressing ATG38 mutants (e.g., AIM mutants)

  • Consider the relationship between ATG38 homodimerization and function

  • Map observed changes to specific autophagy stages using time-course experiments

• Technical validation:

  • Confirm antibody specificity under each experimental condition

  • Verify results using complementary techniques (e.g., fluorescently-tagged ATG38)

  • Include appropriate controls (ATG38-deficient cells, autophagy-defective mutants)

What approaches can resolve contradictory results between different ATG38 antibodies?

When facing contradictory results between different ATG38 antibodies, researchers should:

• Epitope mapping:

  • Determine the exact epitopes recognized by each antibody

  • Assess whether epitopes might be differentially accessible in various experimental conditions

  • Test antibodies against recombinant ATG38 fragments to confirm epitope recognition

• Validation hierarchy:

  • Establish a validation hierarchy using genetic controls (ATG38 knockout/knockdown)

  • Determine which antibodies give expected results in these control experiments

  • Use antibodies recognizing different epitopes to create a consensus pattern

• Functional correlation:

  • Correlate antibody results with functional readouts of autophagy

  • Determine which antibody results best align with established autophagy markers and phenotypes

  • Consider whether contradictions might reveal biologically meaningful states (e.g., conformational changes)

• Technical cross-comparison:

  • Test antibodies side-by-side using identical samples and protocols

  • Systematically vary conditions (fixation, lysis, blocking) to identify method-dependent differences

  • Evaluate batch-to-batch variability of the same antibody

• Orthogonal verification:

  • Confirm key findings using non-antibody methods (fluorescent tagging, mass spectrometry)

  • Create a tagged version of ATG38 and use anti-tag antibodies as reference

  • Consider proximity labeling approaches (BioID, APEX) as alternatives

• Computational analysis:

  • Apply statistical methods to quantify the reliability of each antibody

  • Use machine learning approaches to identify patterns in contradictory results

  • Model the structural basis of contradictions using available structural data

How can researchers integrate ATG38 antibody data with other autophagy markers to obtain a comprehensive view of autophagy dynamics?

Integrating ATG38 antibody data with other autophagy markers requires a multi-layered approach:

• Temporal staging analysis:

  • Create a timeline of marker appearances during autophagy induction

  • Position ATG38 recruitment/activation relative to other events (ULK1/Atg1 activation, Atg9 vesicle recruitment, LC3/Atg8 lipidation)

  • Use synchronized cell populations or microfluidic systems with precise temporal control

• Spatial correlation mapping:

  • Perform multi-color imaging with several markers simultaneously

  • Analyze colocalization patterns quantitatively (Pearson's coefficient, Manders' overlap)

  • Apply super-resolution techniques to determine nanoscale organization

  • Consider the relationship between ATG38 localization and the formation of functional PtdIns3K complex I at the PAS

• Functional interdependence assessment:

  • Use genetic depletion/mutation of ATG38 and measure effects on other markers

  • Conversely, manipulate other autophagy components and assess ATG38 behavior

  • Create an interaction network based on mutual dependencies

  • Consider the importance of the ATG38-Atg8 interaction in promoting autophagosome size and autophagic flux

• Quantitative correlation analysis:

  • Plot levels/distributions of ATG38 versus other markers across conditions

  • Identify threshold effects and non-linear relationships

  • Apply principal component analysis to identify co-varying marker patterns

• Perturbation-response profiling:

  • Apply chemical inhibitors targeting specific autophagy steps

  • Measure the coordinated response of ATG38 and other markers

  • Create a response signature that characterizes different perturbation types

• Single-cell analysis:

  • Measure cell-to-cell variability in ATG38 and other markers

  • Identify subpopulations with distinct autophagy states

  • Correlate heterogeneity patterns across markers to reveal mechanistic connections

• Mathematical modeling:

  • Develop kinetic models incorporating ATG38 and other components

  • Use experimental data to constrain model parameters

  • Make predictions about system behavior under novel conditions

What novel antibody-based techniques are emerging for studying ATG38 interactions in live cells?

Emerging antibody-based techniques for studying ATG38 interactions in live cells include:

• Intrabodies and nanobodies:

  • Single-domain antibodies expressed intracellularly to track ATG38 in living cells

  • Fusion of fluorescent proteins to nanobodies for real-time visualization

  • Inducible intrabody expression systems to disrupt specific interactions on demand

• Split-fluorescent protein complementation:

  • Tagging ATG38 and interaction partners with complementary fragments of fluorescent proteins

  • When proteins interact, fluorescence is reconstituted

  • Allows visualization of specific interactions (e.g., ATG38-Atg8) in real time

• FRET/FLIM-based biosensors:

  • Development of ATG38 conformational sensors using antibody-derived fragments

  • Detection of ATG38 activation states or complex assembly through energy transfer

  • Measurement of interaction kinetics with microsecond resolution

• Optogenetic control of antibody binding:

  • Light-controlled exposure or activation of antibody epitopes

  • Temporal control of ATG38 inhibition in specific cellular compartments

  • Combining with live imaging to correlate inhibition with functional outcomes

• Microfluidic antibody delivery systems:

  • Controlled introduction of antibodies into living cells

  • Temporal modulation of antibody concentration

  • Combination with real-time imaging of autophagy dynamics

• Antibody-mediated degradation approaches:

  • Adaptation of TRIM-Away technology using anti-ATG38 antibodies

  • Rapid depletion of endogenous ATG38 protein in living cells

  • Acute inhibition to study immediate consequences on complex assembly

• Single-molecule tracking with antibody fragments:

  • Quantum dot-labeled antibody fragments for long-term tracking

  • Analysis of ATG38 diffusion dynamics and complex assembly

  • Correlation with membrane remodeling events during phagophore formation

How might ATG38 antibodies contribute to developing therapeutic approaches targeting autophagy?

ATG38 antibodies could contribute to therapeutic approaches through:

• Target validation:

  • Use domain-specific antibodies to identify which ATG38 functions are critical in disease models

  • Determine if blocking specific interactions (e.g., with Atg8 or complex I components) has therapeutic potential

  • Map vulnerability points in autophagy regulation that could be targeted with small molecules

• Diagnostic applications:

  • Develop antibody-based assays to measure ATG38/NRBF2 levels or modifications as biomarkers

  • Create tools to monitor autophagy status in patient samples

  • Identify patient subgroups likely to respond to autophagy-modulating therapies

• Drug discovery platforms:

  • Use antibody competition assays to screen for small molecules targeting ATG38 interfaces

  • Develop high-throughput assays based on ATG38 antibody binding

  • Create conformational biosensors to detect compounds that alter ATG38 structure or function

• Delivery vehicles:

  • Develop antibody-drug conjugates targeting ATG38 in disease states with aberrant expression

  • Create antibody-based nanoparticles for delivering autophagy modulators to specific tissues

  • Use bispecific antibodies to target ATG38-modulating drugs to specific cellular compartments

• Therapeutic antibody development:

  • Engineer antibodies that can selectively inhibit or enhance specific ATG38 functions

  • Develop cell-penetrating antibodies or antibody fragments with therapeutic activity

  • Create stabilized antibody mimetics with improved pharmacological properties

• Combination therapy strategies:

  • Identify synergistic combinations of ATG38-targeting approaches with other therapies

  • Develop biomarkers for patient stratification based on ATG38/NRBF2 status

  • Create rational drug combinations based on ATG38 interaction networks

What computational approaches can enhance ATG38 antibody epitope mapping and selection?

Advanced computational approaches for ATG38 antibody epitope mapping and selection include:

• Structural epitope prediction:

  • Use the crystal structure of the C-terminal homodimerization domain (2.2 Å resolution) for epitope accessibility analysis

  • Implement molecular dynamics simulations to identify stable surface regions

  • Apply ensemble-based approaches to account for protein flexibility

• Machine learning epitope prediction:

  • Train algorithms on known antibody-antigen complexes to predict optimal ATG38 epitopes

  • Incorporate physicochemical properties, evolutionary conservation, and structural features

  • Develop deep learning models that integrate multiple data types

• Antibody repertoire analysis:

  • Use next-generation sequencing of antibody repertoires from immunized animals

  • Identify convergent antibody sequences that may target immunodominant epitopes

  • Apply library-on-library screening approaches similar to those described for antibody-antigen binding prediction

• Active learning for epitope mapping:

  • Implement iterative experimental-computational approaches

  • Use initial epitope mapping data to train predictive models

  • Prioritize subsequent experiments based on model uncertainty

  • Similar approaches have shown up to 35% reduction in required experimental variants

• Network analysis of ATG38 interactions:

  • Model the interaction network of ATG38 with complex I components

  • Identify interface regions likely to be accessible to antibodies

  • Predict effects of antibody binding on complex stability and function

• In silico antibody design:

  • Computationally design antibodies targeting specific ATG38 epitopes

  • Optimize binding affinity and specificity through molecular modeling

  • Perform virtual screening of antibody libraries against ATG38 structural models

• Cross-reactivity prediction:

  • Align sequences of ATG38 from different species to identify conserved regions

  • Predict potential cross-reactivity with related proteins containing MIT domains

  • Design experiments to validate cross-reactivity computationally identified